Author:
Cortés Javier,Caralt Mireia,Delaloge Suzette,Cortes-Funes Hernan,Pierga Jean-Yves,Pritchard Kathleen I.,Bollag David T.,Miles David W.
Reference32 articles.
1. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders;Presta;Cancer Res,1997
2. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
3. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007
4. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of HER2-negative metastatic breast cancer;Miles;J Clin Oncol,2010
5. Miles DW, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Res 2009;69(Suppl. 3):495s [abstract 41].
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献